Applying Biotechnology and Bioengineering to Pediatric Lung Disease: Emerging Paradigms and Platforms.

Kelley L Colvin, Michael E Yeager

Abstract readReview

In one paragraph

Review in Frontiers in pediatrics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Bioengineering lungs: An overview of current methods, requirements, and challenges for constructing scaffolds.Frontiers in bioengineering and biotechnology · 2022
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kelley L ColvinDepartment of Pediatrics-Critical Care, University of Colorado Denver , Denver, CO , USA ; Cardiovascular Pulmonary Research, University of Colorado Denver , Denver, CO , USA ; Department of Bioengineering, University of Colorado Denver , Denver, CO , USA ; Linda Crnic Institute for Down Syndrome, University of Colorado Denver , Denver, CO , USA.

Michael E YeagerDepartment of Pediatrics-Critical Care, University of Colorado Denver , Denver, CO , USA ; Cardiovascular Pulmonary Research, University of Colorado Denver , Denver, CO , USA ; Department of Bioengineering, University of Colorado Denver , Denver, CO , USA ; Linda Crnic Institute for Down Syndrome, University of Colorado Denver , Denver, CO , USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pediatric lung diseases remain a costly worldwide health burden. For many children with end-stage lung disease, lung transplantation remains the only therapeutic option. Due to the limited number of lungs available for transplantation, alternatives to lung transplant are desperately needed. Recently, major improvements in tissue engineering have resulted in newer technology and methodology to develop viable bioengineered lungs. These include critical advances in lung cell biology, stem cell biology, lung extracellular matrix, microfabrication techniques, and orthotopic transplantation of bioartificial lungs. The goal of this short review is to engage the reader's interest with regard to these emerging concepts and to stimulate their interest to learn more. We review the existing state of the art of lung tissue engineering, and point to emerging paradigms and platforms in the field. Finally, we summarize the challenges and unmet needs that remain to be overcome.

Indexed as

bioengineeringextracellular matrixlungpediatricscaffoldstem/progenitor cell

Identifiers

PMID26106589

DOI10.3389/fped.2015.00045

PMCPMC4460801

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.